AstraZeneca announced an agreement to acquire Fusion Pharmaceuticals Inc., a biopharmaceutical company developing next-generation radioconjugates (RCs).
This acquisition marks a major step forward in our ambition to transform cancer treatment and outcomes for patients, by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
The combination of our leadership in oncology with Fusion’s deep expertise and extensive capabilities in actinium-based RCs has the potential to redefine radiotherapy in oncology.
